A systematic overview of chemotherapy effects in breast cancer

Acta Oncologica

Volumn 40, Issue 2-3, 2001, Pages 253-281

  Bergh, J ^a   Jonsson P E ^b   Glimelius, B ^b   Nygren, P ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSYNTHESIS; BONE; CELLS; HEALTH CARE; IMMUNOLOGY; MONOCLONAL ANTIBODIES; PATIENT MONITORING; SURGERY; TOXICITY; TUMORS;

POLYCHEMOTHERAPHY;

CHEMOTHERAPY;

ANTHRACYCLINE; BISANTRENE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; NAVELBINE; PACLITAXEL; PREDNISOLONE; PREDNISONE; TAMOXIFEN; THIOTEPA; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 0034955343     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860151116349     Document Type: Review

References (273)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
2. Polychemotherapy for early breast cancer: An overview of the randomised trials
3. Breast cancer survival rates with mammographic screening: Similar favorable survival rates for women younger and those older than 50 years
4. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
5. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
6. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer
7. ERBB2 oncogene in human breast cancer and its clinical significance
8. Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials
9. Adjuvant radiotherapy in breast cancer. The treatment of lymp node areas
10. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy
11. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: A novel hypothesis based on clinical findings
12. The role of postmastectomy radiotherapy in high-risk breast cancer patients receiving adjuvant systemic therapy
13. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
14. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
15. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis
16. Combination chemotherapy of carcinoma of the breast
17. Systemic therapy of advanced breast cancer
18. Management of metastatic breast cancer
19. Meeting highlights: International consensus panel on the treatment of primary breast cancer
20. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node- positive breast cancer
21. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients by substituting methotrexate in the CMF combination with epirubicin
22. Improved disease- free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node- positive primary breast cancer
23. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer
24. Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies
25. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center Experience
26. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity to high-risk breast cancer patients
27. Results from a randomized adjuvant breast cancer study with high-dose chemotherapy with CTCb supported by autologous bone marrow stem cells vs dose escalated and tailored FEC therapy
28. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure
29. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery
30. Locally advanced breast cancer
31. Dauerheilung des brustkrebses
32. Inflammatory carcinoma of the breast: The case for conservatism
33. Treatment of patients with inflammatory breast cancer
34. The inoperability of inflammatory carcinoma of the breast
35. Primary chemotherapy in the treatment of inflammatory breast carcinoma. A study of 230 cases from the Institut Gustave-Roussy
36. Prognostic factors in inflammatory breast cancer and therapeutic implications
37. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: A Cancer and Leukemia Group B study
38. Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy vs chemotherapy-surgery
39. Randomised trial of chemotherapy vs endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study)
40. Neoadjuvant intra-arterial chemotherapy in locally advanced breast cancer: A prospective randomized study
41. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer
42. Neoadjuvant vs adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6
43. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from NSABP B-18
44. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3 cm. Results of a randomized trial in a single centre
45. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer
46. Pre- and postoperative chemoendocrine treatment with or without postoperative radiotherapy for locally advanced breast cancer
47. Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. A prospective, randomized study
48. Locally advanced breast cancer: Report of phase II study and subsequent phase III trial
49. Locally advanced breast cancer: The contribution of cytotoxic and endocrine treatment to radiotherapy
50. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European organization for research and treatment of cancer randomized phase III trial
51. Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: Randomized clinical study
52. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy
53. Survival of women with metastatic breast cancer at Yale from 1920 to 1980
54. Does more intense palliative treatment improve overall survival in metastatic breast cancer patients?
55. Effect of chemotherapy on survival in metastatic breast cancer
56. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer
57. Does chemotherapy improve survival in advanced breast cancer? A statistical overview
58. The influence of chemotherapy on survival after recurrence in breast cancer-A population-based study of patients treated in the 1950s, 1960s and 1970s
59. Cytotoxic and hormonal treatment for metastatic breast cancer: A systemic review of published randomized trial involving 31510 women
60. Treatment and survival in advanced breast cancer
61. Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy vs tamoxifen alone in postmenopausal women with advanced breast cancer
62. Randomized evaluation of combination chemotherapy vs. observation alone following response or stabilization after oophorectomy for metastatic breast cancer in premenopausal women
63. A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer
64. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone vs tamoxifen plus CMF
65. A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer
66. Ten-year follow-up study of premenopausal women with metastatic breast cancer: An Eastern Cooperative Oncology Group study
67. Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: An Eastern cooperative oncology group study
68. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: Report of the Swiss Group for Clinical Cancer Research
69. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination
70. A randomized comparative trial of combined vs alternating therapy with cytostatic drugs and high-dose medroxyprogesteron acetate in advanced breast cancer
71. Chemotherapy vs chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial
72. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) vs CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen)
73. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B Protocol 8081
74. Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study
75. Dibromodulcitol and adriamycin + / - tamoxifen in advanced breast cancer
76. Mitomycin C, methotrexate, and vincristine with medroxyprogesterone acetate or prednisolone for doxorubicin resistant advanced breast cancer-a randomized control study
77. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer
78. High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer
79. A randomized trial of mitomycin-C (M) vs mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer
80. Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study
81. Combined cytotoxic and progestogen therapy for advanced breast cancer
82. Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study
83. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen
84. Chemotherapy vs combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study
85. Mitomycin C + high-dose medroxyprogesterone vs cyclophosphamide + doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer
86. An evaluation of early or delayed adjuvant chemotherapy in pre-menopausal patients with advanced breast cancer undergoing oophorectomy
87. Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases
88. Peptichemio vs melphalan (L-PAM) in advanced breast cancer
89. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study)
90. Phase II randomized study of paclitaxel vs mitomycin in advanced breast cancer
91. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer
92. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer
93. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma
94. A phase III trial prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer
95. A comparison of mitoxantrone and doxorubicin in breast cancer
96. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer
97. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma
98. Weekly adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial
99. Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-Phenylalanine mustard
100. Single-drug vs combination cytotoxic chemotherapy in advanced breast cancer: A randomized study
101. Evaluation of single-drug vs multiple-drug chemotherapy in the treatment of advanced breast cancer
102. Chemotherapy of advanced breast cancer: A controlled randomized trial of cyclophosphamide vs a four-drug combination
103. The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy vs single drug
104. Doxorubicin vs mitomycin vs doxorubicin plus mitomycin in advanced breast cancer: A randomized study
105. Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life
106. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients
107. Weekly adriamycin vs VAC in advanced breast cancer. A randomized trial
108. Combination chemotherapy and adriamycin in patients with advanced breast cancer
109. Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure
110. Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer
111. Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study
112. Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer
113. VP-16 + adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: A Southwest Oncology Group Study
114. Combination chemotherapy in hormone resistant breast cancer
115. Combination chemotherapy in advanced breast cancer: A randomized trial comparing a three- vs a five-drug program
116. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer
117. Randomized clinical trial of CFP vs CMFP in women with metastatic breast cancer
118. Prednimustine (Sterecyt) vs cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer
119. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: A prospective randomized trial of the Italian Oncology Group for Clinical Research
120. Classical' CMF vs a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
121. A randomized trial of two regimens of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone in advanced breast cancer
122. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer
123. A randomized trial of cyclophosphamide, doxorubicin, and prednisone vs cyclophosphamide, 5-fluorouracil, and presnisone in patients with metastatic breast cancer
124. Chemotherapy vs chemoimmunotherapy (CAF v CAFVP v CMF each +/MER) for metastatic carcinoma of the breast: A CALGB study
125. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma
126. Combination chemotherapy of metastatic breast cancer
127. Response and survival in advanced breast cancer after two non-cross-resistant combinations
128. A randomized study of CAF + TAM (tamoxifen) vs CMF + TAM in metastatic breast cancer
129. A randomized comparative trial of adriamycin vs methotrexate in combination drug therapy
130. A comparison of continuation vs late intensification followed by discontinuation of chemotherapy in advanced breast cancer
131. A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer
132. Comparison of CAF vs CMFP in metastatic breast cancer: Analysis of prognostic factors
133. Mitoxantrone vs doxorubicin in combination chemotherapy for advanced carcinoma of the breast
134. Adriamycin vs methotrexate in five drug combination chemotherapy for advanced breast cancer
135. Vincristine, doxorubicin, and cyclophosphamide vs low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer
136. Comparison of four-combination chemotherapy programs in metastatic breast cancer: Comparison of multiple drug therapy with cytoxan, 5-FU and prednisone vs cytoxan and adriamycin vs cytoxan, 5-FU and adriamycin vs cytoxan, 5-FU and prednisone alternating with cytoxan and adrimycin
137. Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone
138. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: A Southeastern Cancer Study Group project
139. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer
140. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study
141. Mitoxantrone, 5-fluorouracil, and high-dose leucovorin (NFL) vs intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: A randomized phase II trial
142. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer
143. Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: A randomised clinical trial
144. Epirubicin vs mitroxantrone in combination chemotherapy for metastatic breast cancer
145. High-intensity therapy vs low-intensity therapy in advanced breast cancer patients
146. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer
147. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
148. Chemotherapy of advanced breast cancer: A randomized trial of vincristine, adriamycin, and cyclophosphamide (VAC) vs cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP)
149. Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study
150. Comparison of induction chemotherapies for metastatic breast cancer
151. Advances in research and treatment
152. Current status of epirubicin (farmorubicin) in the treatment of solid tumours
153. Decreased efficacy of cyclophosphamide, and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months
154. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group Study
155. A prospective randomized phase 111 trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin
156. Weekly epirubicin vs doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial
157. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer
158. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer
159. Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer
160. Mitoxantrone vs doxorubicin in advanced breast cancer: A randomized cross-over trial
161. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial
162. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer
163. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity
164. A prospective randomized trial of doxorubicin vs idarubicin in the treatment of advanced breast cancer
165. Comparative phase II study of idarubicin vs doxorubicin in advanced breast cancer
166. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) vs cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer
167. Advanced breast cancer: A randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine
168. Vindesine-epirubicin vs vindesine-mitoxantrone in metastatic breast cancer
169. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer
170. Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: A comparative randomized multicenter study in metastatic breast carcinoma
171. Adriamycin, cyclophosphamide and vindesine (ACV) vs mitoxantrone, cyclophosphamide and vindesine (NCV) in advanced breast cancer
172. Cyclophosphamide and fluorouracil combined with mitoxantrone vs doxorubicin for breast cancer: Superiority of doxorubicin
173. A randomized, prospective, comparative, multicentre trial of a single combination vs alternating combinations of antitumour drugs in advanced breast cancer
174. Combination chemotherapy for metastatic or recurrent carcinoma of the breast-a randomized phase III trial comparing CAF vs VATH vs VATH alternating with CMFVP: Cancer and Leukemia Group B study 8281
175. Sequential vs alternating regimens in the treatment of advanced breast cancer
176. Combination vs sequential single agent chemotherapy in advanced breast cancer: Associations with metastatic sites and long-term survival
177. Combination chemotherapy vs single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial
178. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial
179. Fluorouracil, doxorubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: A multicentric randomized clinical study
180. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: Results from a multicenter prospective randomized trial
181. Conventional vs cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: Result of a randomized cooperative trial
182. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer
183. Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: A double-blind randomized study
184. Increasing the response rate to cytotoxic chemotherapy by endocrine means
185. A randomized trial of aminoglutethimide + estrogen before chemotherapy in advanced breast cancer
186. Comparison of 5-day, 1-day, and 2-day cyclical combination chemotherapy in advanced breast cancer
187. Treatment of advanced breast carcinoma with 5-fluorouracil: A randomized comparison of two routes of delivery
188. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma
189. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer. A randomized trial comparing weekly and every-4-week administration
190. A dose intensity study of epirubicin weekly for disseminated breast cancer
191. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): A very active and well-tolerated outpatient regimen
192. Improving the quality of life during chemotherapy for advanced breast cancer, a comparison of intermittent and continuous treatment strategies
193. Continuous chemotherapy in responsive metastatic breast cancer: A role for tumour markers?
194. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer
195. Interrupted vs continuous chemotherapy in patients with metastatic breast cancer
196. Mitomycin and tamoxifen vs mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer
197. Vindesine in the treatment of refractory breast cancer: Improvement in therapeutic index with continuous 5-day infusion
198. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
199. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
200. Prospective randomised trial of docetaxel vs mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
201. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with cross-over on progression by the Scandinavian Breast Group
202. Cisplatin and VP16 in metastatic breast carcinoma as a third-line chemotherapy: A randomized study comparing low vs high-dose of cisplatin
203. Is there a role of intensive therapy in breast cancer?
204. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
205. High-dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer - A review
206. High-dose chemotherapy with stem-cell rescue for the treatment of breast cancer
207. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer
208. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
209. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer
210. Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients
211. A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy
212. Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer
213. The importance of dose intensity in chemotherapy of metastatic breast cancer
214. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer
215. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
216. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors-5-year follow-up results of French Adjuvant Study Group 05 randomized trial
217. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
218. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
219. Lack of efficacy of adjuvant high-dose(HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC)-A randomized trial
220. A propsective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary nodes
221. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high- risk breast cancer: A randomised trial
222. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish breast cancer cooperative group
223. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
224. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma
225. Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems
226. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial
227. Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules
228. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial
229. Evaluation of high-dose vs standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study
230. Different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil: A randomised study in advanced breast cancer
231. Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life
232. A randomized study of intensive vs moderate chemotherapy programs in metastatic breast cancer
233. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer
234. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial
235. Primary high-dose chemotherapy for metastatic breast cancer: Update and analysis of prognostic factors
236. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
237. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
238. High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer
239. Survival from first recurrence: Relative importance of prognostic fators in 1,015 breast cancer patients
240. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies
241. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer
242. Chemotherapy for advanced disease
243. Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies?
244. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
245. Much ado about not... enough data: High-dose chemotherapy with autologous stem ceil rescue for breast cancer
246. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer
247. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support
248. A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high-dose mitoxantrone therapy
249. Prophylactic filgrastim (G-CSF) during mutimycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer
250. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer
251. Comparative study of dose escalation vs interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer
252. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer
253. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer
254. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients
255. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high-dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapynaive patients with locally advanced or metastatic breast-cancer
256. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer
257. Combination of levamisole immunotherapy and polychemotherapy in advanced breast cancer
258. Levamisole: As adjuvant to cyclic chemotherapy in breast cancer
259. Ineffectiveness of levamixole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: A Southeastern cancer study group trial
260. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunohterapy for metastatic breast cancer. A prospective, randomized trial
261. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
262. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
263. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer
264. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis
265. Adjuvant chemotherapy for breast cancer: Side-effects and quality of life
266. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer
267. Long-term quality of life after breast cancer: Comparison of 8-year survivors with population controls
268. Characteristics and correlates of fatigue after adjuvant therapy for breast cancer
269. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning
270. Cognitive function in breast cancer patients receiving standard-dose adjuvant chemotherapy
271. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy
272. Do patients with advanced breast cancer benefit from chemotherapy?